AlessandroSantinMD

Obstetrics & Gynecology • New Haven, CT

Professor, Obstetrics & Gynecology, Yale University School of Medicine

Join to view full profile

Dr. Santin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Santin's full profile

Already have an account?

Office
20 York St
New Haven, CT 06510
Phone+1 203-737-4450

Fax+1 203-737-4339

Education & Training

Yale School of MedicineClass of 1989

Certifications & Licensure

AR State Medical License 1998 - 2026
CT State Medical License 2007 - 2025

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2014
Top Doctors: New York Metro Area Castle Connolly, 2010-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
America's Top Doctors for Cancer Castle Connolly, 2009-2013
Join now to see all

Clinical Trials

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer Start of enrollment: 2011 Jun 01
Completed
Phase 2
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Start of enrollment: 2015 May 18
Active, not recruiting
Phase 2
A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma Start of enrollment: 2015 Jun 01
Recruiting
Phase 2
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer Start of enrollment: 2016 Sep 16
Completed
Phase 2
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab Start of enrollment: 2017 Apr 03
Completed
Phase 2
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer Start of enrollment: 2020 Jul 15
Recruiting
Phase 2
A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma Start of enrollment: 2020 Mar 17
Recruiting
Phase 2
Roles: Contact, Principal Investigator, Sponsor-Investigator
Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) Start of enrollment: 2016 Jul 01
Completed
Phase 2
Roles: Contact, Principal Investigator
A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients Start of enrollment: 2024 Jan 08
Recruiting
Phase 2
Roles: Principal Investigator, Sponsor-Investigator, Contact
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer Start of enrollment: 2023 Jun 02
Recruiting
Phase 2
Roles: Sponsor-Investigator, Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma.
Daniela E Matei, Danielle M Enserro, Marcus E Randall, David Mutch, William Small
Journal of Clinical Oncology. 2024-12-19
Uterine teratoma and the role of short-tandem repeat genotyping in understanding origins.
Abdelrahman AlAshqar, Vijaya Kadam Maruthi, Rita Abi-Raad, Michelle Greenman, Pei Hui
Gynecologic Oncology Reports. 2024-12-01
Utility of next generation sequencing to unequivocally establish clonality in synchronous vs metastatic endometrial and ovarian carcinomas.
Michelle Greenman, Stefania Bellone, Tobias Hartwich, Natalia Buza, Alessandro D Santin
Gynecologic Oncology Reports. 2024-12-01

Journal Articles

Phase II Evaluation of Nivolumab in the Treatment of Persistent or Recurrent Cervical Cancer (NCT02257528/NRG-GY002)
Alessandro D Santin, Michael Frumovitz, Natalia Buza, Samir Khleif, Elena S Ratner, Roisin E O'Cearbhaill, Michael Birrer, Gynecologic Oncology

Lectures

A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Sacituzumab Govitecan Shows Promise in Advanced Endometrial CancerAugust 15th, 2024
2023 ‘Top Doctors’ List Features Over 250 Yale Medicine PhysiciansMay 3rd, 2023
Connecticut Magazine’s 2023 “Top Doctors” Issue Recognizes 82 Smilow Cancer Hospital and Yale Cancer Center PhysiciansMay 1st, 2023
Join now to see all